NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $15.26 -0.18 (-1.17%) (As of 09/6/2024 08:48 PM ET) Add Compare Share Share Today's Range$14.51▼$15.6550-Day Range$10.49▼$15.8052-Week Range$2.05▼$19.05Volume414,400 shsAverage Volume615,619 shsMarket Capitalization$950.13 millionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside29.8% Upside$19.80 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 6 Articles This WeekInsider TradingAcquiring Shares$184,656 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.87) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.50 out of 5 starsMedical Sector655th out of 909 stocksSurgical & Medical Instruments Industry80th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CATX. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 1.8 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Perspective Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $184,656.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.87) to ($0.98) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.Click here to review my research and unique strategy to score potential profits from this under-the- About Perspective TherapeuticsPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesSeptember 6 at 10:32 AM | seekingalpha.comPerspective gets FDA fast track status for radiopharmaceutical VMT01September 5, 2024 | markets.businessinsider.comPerspective Therapeutics: FDA Grants Fast Track Designation For Development Of 212Pb VMT01September 9, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 5, 2024 | globenewswire.comPerspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive MelanomaSeptember 4, 2024 | americanbankingnews.comPerspective Therapeutics' (CATX) "Overweight" Rating Reiterated at Cantor FitzgeraldAugust 28, 2024 | globenewswire.comPerspective Therapeutics to Participate in Upcoming Investor Conferences in SeptemberAugust 26, 2024 | seekingalpha.comTScan Therapeutics: Speculative Buy With Near-Term Catalysts In OncologyAugust 16, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)September 9, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 14, 2024 | finance.yahoo.comCATX Jan 2025 12.500 call (CATX250117C00012500)August 14, 2024 | markets.businessinsider.comBuy Rating Justified by Perspective Therapeutics’s Promising Clinical Data and Strategic ExpansionAugust 14, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Perspective Therapeutics (CATX)August 13, 2024 | markets.businessinsider.comBuy Rating on Perspective Therapeutics: Advancing Clinical Programs and Strong Financials Promise Value CreationAugust 12, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 ResultsAugust 12, 2024 | markets.businessinsider.comHere's what to expect from Perspective Therapeutics's earningsAugust 5, 2024 | seekingalpha.comThe Prognosis For Perspective TherapeuticsJuly 30, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming Investor Conferences in AugustSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:CATX CUSIPN/A CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$27.00 Low Stock Price Target$14.00 Potential Upside/Downside+29.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net MarginsN/A Pretax Margin-3,641.05% Return on Equity-32.87% Return on Assets-28.06% Debt Debt-to-Equity RatioN/A Current Ratio27.73 Quick Ratio27.73 Sales & Book Value Annual Sales$1.43 million Price / Sales664.43 Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book3.02Miscellaneous Outstanding Shares62,263,000Free Float60,071,000Market Cap$950.13 million OptionableOptionable Beta1.44 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsAxonicsNASDAQ:AXNXEnvistaNYSE:NVSTTandem Diabetes CareNASDAQ:TNDMInari MedicalNASDAQ:NARILivaNovaNASDAQ:LIVNView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 13,250,683 shares on 8/19/2024Ownership: 0.325%Deerfield Management Company L.P. Series CSold 25,359,873 shares on 8/15/2024Ownership: 4.526%Affinity Asset Advisors LLCSold 4,550,000 shares on 8/15/2024Ownership: 0.883%The Manufacturers Life Insurance Company Bought 18,842 shares on 8/15/2024Ownership: 0.030%Point72 DIFC LtdBought 11,842 shares on 8/14/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $11.90 at the start of the year. Since then, CATX shares have increased by 28.2% and is now trading at $15.26. View the best growth stocks for 2024 here. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million for the quarter. When did Perspective Therapeutics' stock split? Perspective Therapeutics shares reverse split on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Top institutional shareholders of Perspective Therapeutics include Deerfield Management Company L.P. Series C (4.53%), Marshall Wace LLP (2.06%), Affinity Asset Advisors LLC (0.88%) and Ally Bridge Group NY LLC (0.64%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Robert F Williamson III, Jonathan Robert Hunt and Johan M Spoor. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CATX) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CATX Stock Alerts